RT Journal Article
T1 Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection.
A1 Escudero-Sanchez, Rosa
A1 Ruiz-Ruizgomez, Maria
A1 Fernandez-Fradejas, Jorge
A1 Garcia-Fernandez, Sergio
A1 Olmedo-Samperio, Maria
A1 Cano-Yuste, Angela
A1 Valencia-Alijo, Angela
A1 Diaz-Pollan, Beatriz
A1 Rodriguez-Hernandez, Maria Jesus
A1 Merino-De-Lucas, Esperanza
A1 Martin-Segarra, Oriol
A1 Saez-Bejar, Carmen
A1 Armiñanzas-Castillo, Carlos
A1 Gutierrez-Gutierrez, Belen
A1 Rodriguez-Pardo, Dolors
A1 Ramos-Martinez, Antonio
A1 De-La-Torre-Cisneros, Julian
A1 Lopez-Medrano, Francisco
A1 Cobo-Reinoso, Javier
K1 C. difficile infection
K1 Clostridioides difficile
K1 Clostridium difficile
K1 Bezlotoxumab
K1 Recurrence
AB Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI.
PB MDPI
SN 2077-0383
YR 2020
FD 2020-11-30
LK http://hdl.handle.net/10668/16868
UL http://hdl.handle.net/10668/16868
LA en
NO Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, et al. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med. 2020 Dec 22;10(1):2
NO Supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011) co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020.
DS RISalud
RD Apr 19, 2025